Compounds as pde iv and tnf inhibitors

Details Compounds as pde iv and tnf inhibitors Compounds as pde iv and tnf inhibitors

C - Chemistry, Metallurgy

07

C

C07C 235/56 (2006.01) A61K 31/00 (2006.01) C07C 43/225 (2006.01) C07C 43/247 (2006.01) C07C 217/58 (2006.01) C07C 237/30 (2006.01) C07C 255/60 (2006.01) C07C 323/42 (2006.01) C07C 327/48 (2006.01) C07D 213/65 (2006.01) C07D 213/70 (2006.01) C07D 213/75 (2006.01) C07D 213/82 (2006.01) C07D 213/89 (2006.01) C07D 239/42 (2006.01) C07D 241/20 (2006.01) C07D 261/14 (2006.01) C07D 275/03 (2006.01) C07D 401/12 (2006.01) C07D 413/12 (2006.01)

Patent

CA 2160928

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production of physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with poathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

Cette invention concerne un composé [di(éther ou thioéther)hétéroaryle ou aryle fluoro substitué] ou un N-oxyde de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci, qui est utilisé pour inhiber la production ou les effets physiologiques du facteur de nécrose tumorale (TNF) dans le traitement d'un patient souffrant d'un état pathologique associé à un excès physiologiquement nocif du facteur de nécrose tumorale (TNF). Les composés de la présente invention inhibent également l'AMP cyclique-phosphodiestérase et sont utilisés dans le traitement d'un état pathologique associé à des pathologies qui sont modulées par l'inhibition de l'AMP cyclique-phosphodiestérase, ces pathologies comprenant les maladies inflammatoires et auto-immunes, notamment l'AMP cyclique-phosphodiestérase du type IV. La présente invention concerne par conséquent l'utilisation pharmacologique de ces composés dans l'inhibition du TNF et/ou de l'AMP cyclique-phosphodiestérase, les compositions pharmacologiques comprenant les composés et leurs procédés de préparation.

Affiliated with

Also associated with

Rating

Compounds as pde iv and tnf inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds as pde iv and tnf inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as pde iv and tnf inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1357521